


IRAK4-IN-7

Chemical Properties

CAS No. : 1801343-74-7
 Formula: C₂₁H₁₉N₇O₃
 Molecular Weight: 417.42
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	IRAK4-IN-7 (CA-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model.
Targets(IC50)	IRAK
In vitro	CA-4948 was previously shown to exhibit dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models using cell lines OCI-LY3 and OCI-LY10[1].
In vivo	CA-4948 has antitumor activity in ABC-type diffuse large B cell lymphoma patient-derived xenograft (PDX) mouse models[2].

Solubility Information

Solubility	DMSO: 13.89 mg/mL (33.28 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.4 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3957 mL	11.9783 mL	23.9567 mL
5 mM	0.4791 mL	2.3957 mL	4.7913 mL
10 mM	0.2396 mL	1.1978 mL	2.3957 mL
50 mM	0.0479 mL	0.2396 mL	0.4791 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Robert N. Booher, et al. Abstract 1168: Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma. AACR Annual Meeting 2017; April 1-5, 2017;
Booher, R.N., Samson, M.E., Xu, G.-X., et al. Abstract 1168: Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma. Cancer Res. 77(13 Supp), 1168 (2017).

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481